Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025 Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65%